This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Roch AG subsidiary Genentech filed a lawsuit against Amgen claiming the Thousand Oaks-based company obstructed its investigation of whether the biosimilar Amgen is developing for Genentech’s cancer treatment Avastin violates the company’s patents, according to reports Feb. 20. Sales for Avastin, a treatment for lung, colon, ovarian and other types of cancer, reached $6.8 billion Read More →
Pharmaceuticals Amgen and Allergan announced positive Phase 3 study results of their new drug ABP 215 on Sept. 23. The drug, used to treat lung cancer, is being developed as a biosimilar to Roche Holding AG’s Avastin. ABP 215 showed clinical safety and effectiveness compared to Avastin. “Lung cancer is the leading cause of cancer Read More →